Digital Repository

Ensemble techniques for predictive modeling of leishmanial activity via molecular fingerprints

Show simple item record

dc.contributor.author Nalband, Saif en_US
dc.contributor.author KIRATKAR, PALLAVI en_US
dc.contributor.author Gupta, Maulik en_US
dc.contributor.author Gambhir, Mansi en_US
dc.contributor.author Sonam, Surabhi en_US
dc.contributor.author Robert, Femi en_US
dc.contributor.author Prince, A. Amalin en_US
dc.date.accessioned 2025-10-31T04:50:00Z
dc.date.available 2025-10-31T04:50:00Z
dc.date.issued 2025-10 en_US
dc.identifier.citation BMC Medical Informatics and Decision Making, 25, 378. en_US
dc.identifier.issn 1472-6947 en_US
dc.identifier.uri https://doi.org/10.1186/s12911-025-03041-4 en_US
dc.identifier.uri http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/10493
dc.description.abstract Background: Leishmaniasis, a neglected tropical disease caused by Leishmania protozoan parasites and transmitted by sandflies, poses a significant global health challenge, especially in resource-limited environments. The life cycle of the parasite includes crucial amastigote and promastigote stages, each contributing importantly to the infection process. The current therapies for leishmaniasis face limitations due to considerable side effects and the rise of drug-resistant strains, underscoring the pressing need for new, effective, and safe treatment options. Recent advancements in leishmaniasis vaccine development include live attenuated vaccines, recombinant vaccines, and the use of synthetic biology. These approaches aim to induce robust immune responses while ensuring safety. Controlled human infection studies are also being explored to accelerate vaccine development. However, a licensed vaccine remains elusive. Method: This study introduces a novel method for drug discovery targeting leishmaniasis, employing machine learning and cheminformatics to forecast the efficacy of compounds against Leishmania promastigotes. A detailed dataset consisting of 65,057 molecules sourced from the PubChem database is utilized, with the Alamar Blue-based assay applied to assess drug susceptibility. The data encoding relies on molecular fingerprints derived from Simplified Molecular Input Line Entry System (SMILES) notations. We employed three distinct fingerprint algorithms, Avalon, MACCS Key, and Pharmacophore, for the development of machine learning models. Various algorithms, including random forest, multilayer perceptron, gradient boosting, and decision tree, are utilized to create models that effectively classify molecules as either active or inactive based on their structural and chemical characteristics, which could significantly impact the drug discovery process for leishmaniasis. Results: We additionally introduced a model based on ensembles, achieving a peak accuracy of 83.65% and an area under the curve of 0.8367. This study offers significant promise in enhancing drug discovery efforts focused on tackling the global issue of leishmaniasis. Conclusion: Furthermore, the proposed approach has the potential to serve as a framework for addressing other overlooked tropical diseases, offering a promising alternative to conventional drug discovery methods and their associated difficultie en_US
dc.language.iso en en_US
dc.publisher BioMed Central Ltd en_US
dc.subject Leishmanania en_US
dc.subject Machine learning en_US
dc.subject Molecular fingerprints en_US
dc.subject Ensemble learning en_US
dc.subject 2025-OCT-WEEK4 en_US
dc.subject TOC-OCT-2025 en_US
dc.subject 2025 en_US
dc.title Ensemble techniques for predictive modeling of leishmanial activity via molecular fingerprints en_US
dc.type Article en_US
dc.contributor.department Dept. of Biology en_US
dc.identifier.sourcetitle BMC Medical Informatics and Decision Making en_US
dc.publication.originofpublisher Foreign en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Repository


Advanced Search

Browse

My Account